Lenalidomidă Sandoz (Lenalidomide)

• Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.
• Multiple myeloma: improves progression‑free and overall survival when combined with dexamethasone or proteasome inhibitors in relapsed or refractory disease.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission in patients with low‑ or intermediate‑risk disease.
• Mantle cell lymphoma: contributes to response rates as part of combination regimens in patients with relapsed or refractory disease.

• Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in reduced proliferation of malignant plasma cells, enhanced natural‑killer and T‑cell mediated immunity, inhibition of angiogenesis, and promotion of apoptotic pathways. The combined immunomodulatory and anti‑angiogenic actions contribute to its antineoplastic activity.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: decreased neutrophil count leading to infection risk.
• Thrombocytopenia: reduced platelet levels increasing bleeding tendency.
• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: potentially life‑threatening clot formation.
• Secondary primary malignancies: emergence of new cancers such as acute leukemia.
• Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Prior to initiating Lenalidomidă Sandoz, several safety considerations should be reviewed.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women and ensure effective contraception.
• Renal impairment: assess kidney function; dose may need adjustment in moderate to severe impairment.
• Hematologic monitoring: perform baseline and regular complete blood counts to detect cytopenias.
• Thromboembolic risk: evaluate patient history; consider prophylactic anticoagulation when risk factors present.
• Drug interactions: avoid concurrent use with strong CYP3A4 inducers such as rifampin.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomidă Sandoz can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma concentrations, compromising therapeutic effect.
• Anticoagulants (warfarin, direct oral anticoagulants): increased risk of thrombotic events; monitor coagulation parameters closely.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise lenalidomide levels, requiring dose review.
• Immunosuppressants (e.g., cyclosporine, tacrolimus): potential additive immunomodulatory effects; monitor for infections.
• Vaccines: live attenuated vaccines should be avoided during treatment.